Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Degenerative neurological disorders

Cannabinoids could help manage spasticity in motor neurone disease

After six weeks, researchers found that patients using an oromucosal spray containing delta-9-tetrahydrocannabinol and cannabidiol had improved spasticity compared with the placebo group, in which patients found their spasticity deteriorated.

Physician testing spasticity in motor neurone patient


While the cannabinoid spray improved spasticity and pain in patients compared with those given placebo, there were no significant differences in sleep quality, spasms or strength

An oral spray containing cannabinoids is effective at reducing spasticity symptoms in motor neurone disease (MND), study results published in The Lancet Neurology (13 December 2018) have shown[1].

The randomised, double-blind, phase II trial involved 60 patients who were randomly assigned to placebo or an oromucosal spray containing delta-9-tetrahydrocannabinol and cannabidiol. Patients self-escalated their dose during the first two weeks and then maintained that dose for the remaining four weeks of the trial.

The researchers found that after six weeks, spasticity (measured on the Modified Ashworth Scale) had improved in the active treatment group by a mean of 0.11, but deteriorated in the placebo group by a mean of 0.16, leading to a significant difference in effect between the two groups. There was also a significant reduction in patient-reported pain, but no differences in other disease-related measures, such as sleep quality, spasms or strength.

Oromucosal cannabinoid sprays have been approved in several countries for symptomatic treatment of spasticity in multiple sclerosis, but they have not previously been explored for spasticity in MND.

“Further confirmatory phase III studies are warranted to confirm our findings, and more clinical research into the potential neuroprotective effect of cannabinoids in slowing disease progression in motor neurone disease is warranted,” the authors said.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206059

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.